Congress has been holding hearings on pharma patents & med prices, along with U.S. Patent & Trademark Office fee-setting & oversight. During the hearings, our pharma innovators are accused of abusing the patent system when inventing & improving new meds. ipwatchdog.com/2026/10/04/wh…

The Trump administration just inked deals with nine more pharmaceutical companies that agreed to offer Medicaid the same low prices that foreign countries pay. In exchange, President Donald Trump promised to spare these manufacturers from tariffs. washingtonexaminer.com/op-ed…

Wealthy allies have been freeloading on U.S. drug innovation for years. Trump is finally doing something about it. Grace Reilly breaks down an op-ed on the wealthy countries that let Americans fund a disproportionate share of the world's drug research. apple.co/4hOxlLh

About 72% of American adults are overweight or obese & roughly 12% have Type 2 diabetes. Only half of European adults are overweight or obese & just 7% have type 2 diabetes. Yet, Americans tend to survive longer than Europeans with the same disease. bit.ly/47HjzoY

Recently Pres. Trump welcomed Chinese President Xi Jinping to D.C. for the first time in a decade. Tariffs, Iran & rare earth minerals were among the issues that dominated their summit. But another arena of competition deserves D.C.’s attention: biotech. statnews.com/2026/09/30/chin…

For 45+ years the Bayh-Dole Act has served as the foundation of the U.S. tech transfer system & a backbone of innovation. The act has enabled & incentivized the collaboration needed to transform scientific discoveries into new tech & more. Read the report bayhdolecoalition.org/wp-con…

The U.S. Investments in Medical & Health Research & Development report is designed to fill a gap in industry info by providing a picture of funding across sectors. Unusual developments are accounted for in interpreting what the numbers do & don't tell us. bit.ly/3VYhD8W

Pres. Trump just secured 9 new pricing agreements with drug manufacturers that may help reduce what we pay for many meds, demonstrating his commitment to lowering drug prices. His dedication & desire to negotiate with companies individually is commendable. foxnews.com/opinion/trump-lo…

When President Biden signed the Inflation Reduction Act into law, his administration promised it would make prescription drugs more affordable and accessible for seniors. Yet the results tell a different story. thehill.com/opinion/healthca…

Trump's admin just launched a “Section 301” investigation into Germany’s pharma pricing practices. The move begins a process to address foreign free-riding & helps the broader goal of ensuring wealthy countries pay their fair share for global innovation. washingtonexaminer.com/op-ed…

Cancer patients in Europe face record-setting wait times when seeking cutting-edge treatment. Once European regulators approve a new oncology drug, it takes 655 days, on average, for their gov-run insurance systems to start offering it to patients. washingtonexaminer.com/op-ed…

In Dec. 2025, the U.K & U.S. concluded a major trade agreement in the pharma sector: a model demonstrating how a government can simultaneously improve patient access, attract investment in the life sciences & strengthen its position in a global economy. bit.ly/4yFOM7x

It’s been 4 yrs since Biden signed the Inflation Reduction Act into law. Back then, supporters & critics acknowledged the law’s price controls on meds would deter biotech research investments. They disagreed only about how many new drugs would be foregone. dcjournal.com/whats-the-dama…

For over a year, German officials have obstructed one of the Trump administration's most important reform initiatives. And the president's patience just ran out. newsweek.com/to-force-other-…

You’ve probably heard the expression, “all hat, no cattle.” It describes someone who wears trappings of a cowboy but has never stepped foot on a ranch. Well, the phrase also applies to some urban hospitals. gingrich360.net/p/all-hat-no…

Congress should be cautious about turning MFN drug pricing into permanent law. Codification could lock in an opaque, foreign-reference pricing regime that may deliver headline savings while weakening U.S. biomed innovation & complicating patient access. tampafp.com/op-ed-mfn-drug-p…

In the medical world, innovation in the free marketit saves lives. Drugmakers Merck & Moderna announced their latest medical breakthrough: a personalized vaccine that helps prevent the recurrence of skin cancer. The preliminary findings are exciting. washingtonpost.com/opinions/…

PFCD's Ken Thorpe & Daneen Sekoni, VP of Policy & Advocacy at Cancer Support Community discuss what proposed MFN drug pricing policies could mean for people living with cancer. They explore treatment accessibility, health equity & future breakthrough meds. youtube.com/watch?v=xktQ6x1G…

American leadership in biotech resulted from decades of investment. It consists of a market-driven system that rewards critically necessary innovation & a regulatory framework built to move science from lab to patient faster than anywhere else in globally. washingtontimes.com/news/202…

There's never a good time to be diagnosed with cancer. But for the millions who'll be diagnosed this year, the odds of beating it have never been better. 99%+ of prostate cancer patients diagnosed between 2005 & 2014 were still alive a decade later. realclearhealth.com/articles…